Form 4: DaVita Director Acquires 332 Shares Under 10b5-1 Plan

DaVita Inc. Director Adam H. Schechter acquired 332 shares of common stock on March 15, 2026, as part of a pre-arranged trading plan.

Summary

• Adam H. Schechter, a Director of DaVita Inc. (DVA), acquired 332 shares of the company's common stock.
• The transaction occurred on March 15, 2026, and was an acquisition (Code A).
• The shares were acquired at a price of $0, indicating a grant, award, or similar non-cash transaction.
• Following this transaction, Adam H. Schechter directly beneficially owns a total of 5,442 shares of DaVita Inc. common stock.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director's acquisition of shares, even if granted, generally indicates continued alignment with shareholder interests and confidence in the company's long-term value.

Positives

• The acquisition of shares by a director can signal confidence in the company's future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-scheduled, non-discretionary acquisition, which can reduce concerns about opportunistic insider trading.

Negatives

• The acquisition price of $0 suggests the shares were granted rather than purchased, which does not represent a direct cash investment by the director.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled transaction date.

Industry Context

StockSavvy.ai notes that insider transactions, even those under 10b5-1 plans, are routinely disclosed for all publicly traded companies. This specific transaction for DaVita Inc., a major provider of kidney care services, reflects a director's planned equity activity rather than a broader industry trend.

Comparison to Industry Standards

• This Form 4 filing is standard for reporting insider transactions and aligns with SEC disclosure requirements for directors and officers across all industries.
• The use of a Rule 10b5-1 plan is a common practice among corporate insiders to manage stock transactions in compliance with insider trading laws, similar to practices at companies like Fresenius Medical Care (FMS) or Baxter International (BAX) in the healthcare sector.

Related Party Transactions

• The acquisition of shares by Adam H. Schechter, a Director of DaVita Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The director's increased ownership aligns their interests more closely with those of other shareholders, potentially signaling confidence in the company's future.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing reports a routine insider acquisition of shares, likely a grant, under a pre-arranged plan. While it shows a director's continued stake in the company, it does not present new fundamental information significant enough to warrant a change in investment recommendation. Investors should consider this as a minor, expected event within the broader context of DaVita's financial performance and strategic outlook.

Keywords

DaVita Inc., DVA, Adam H. Schechter, Director, Insider Trading, Form 4, Stock Acquisition, Rule 10b5-1 Plan, Common Stock, Beneficial Ownership